Corcept Therapeutics (CORT) AI Stock Analysis

• Market Cap: $7.92B
• Dividend Yield: N/A
• Average Volume (3M): 672.00K
• Price to Earnings (P/E): 66.9
• Beta (1Y): 0.38
• Revenue Growth: 25.71%
• EPS Growth: 4.48%
• Country: US
• Employees: 500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.29
• Shares Outstanding: 105,371,730
• 10 Day Avg. Volume: 706,303
• 30 Day Avg. Volume: 672,004
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 11.88
• Enterprise Value/Gross Profit: 12.08
• Enterprise Value/Ebitda: 81.93
• 1Y Price Target: $135.25
• Price Target Upside: 69.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 76 Outperform
• Price Target: $81.00 ▲(1.50% Upside)

Corcept Therapeutics' overall stock score is driven by strong financial performance and positive earnings call sentiment. While the technical analysis suggests a neutral trend, the high valuation presents a potential risk. The company's strategic expansions and promising drug pipeline support a positive outlook, despite some operational challenges.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and sustainability.

Pipeline Expansion

The advancement of new drug applications suggests a robust pipeline, potentially leading to future revenue streams and market leadership in niche areas.

Cash Flow Management

Efficient cash conversion supports operational flexibility and investment capacity, ensuring the company can sustain growth and manage unforeseen challenges.

Negative Factors

Net Income Decline

A decline in net income, even if slight, may indicate pressure on profitability, which could affect future investment and growth capabilities.

Pharmacy Capacity Issues

Ongoing capacity issues with pharmacy vendors could hinder revenue realization and customer satisfaction, impacting long-term sales growth.

Patent Litigation

The unresolved patent litigation poses a risk to Korlym's market exclusivity, potentially affecting future revenue and competitive positioning.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

How the Company Makes Money

Corcept Therapeutics generates revenue primarily through the sales of Korlym, its approved drug for Cushing's syndrome. The company earns income from product sales to healthcare providers and patients, and it may also receive royalties or milestones from partnerships related to its drug development pipeline. In addition, Corcept has engaged in collaborations with other pharmaceutical companies, which can provide funding and resources for research and development, thereby contributing to its overall revenue. These partnerships may involve sharing in the profits of jointly developed drugs or receiving upfront payments and milestones based on development progress.

Corcept Therapeutics Financial Statement Overview

Summary

Corcept Therapeutics demonstrates strong profitability with high margins and impressive revenue growth. The company maintains a solid financial structure with low leverage and effective cash flow management, supporting its financial stability.

Income Statement

Corcept Therapeutics demonstrates strong profitability with a Gross Profit Margin consistently above 95% and a solid Net Profit Margin around 18%. The company has shown impressive revenue growth, with a 43% increase from 2022 to 2023 and a smaller yet healthy 6% growth in TTM (Trailing-Twelve-Months). While EBIT and EBITDA margins have slightly declined in the TTM period, they remain robust at approximately 14%.

Balance Sheet

The company maintains a sound financial structure with a Debt-to-Equity Ratio well below 0.02, indicating low leverage. The Equity Ratio is strong, consistently above 75%, reflecting a high level of equity relative to total assets. ROE is healthy at around 21% in the TTM period, though slightly lower compared to previous years, indicating solid return on equity investments.

Cash Flow

Corcept Therapeutics exhibits strong cash flow management. The Operating Cash Flow to Net Income Ratio is consistently above 1, indicating efficient conversion of income to cash. The Free Cash Flow to Net Income Ratio is also robust above 1 in the TTM period. Despite a decrease in Operating Cash Flow compared to 2024, Free Cash Flow remains strong, with a minor decline of 8% in the TTM period, reflecting solid cash flow generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	716.08M	675.04M	482.38M	401.86M	365.98M	353.87M
Gross Profit	704.42M	664.16M	475.89M	396.47M	360.70M	348.29M
EBITDA	103.84M	136.95M	108.32M	113.89M	127.95M	130.44M
Net Income	132.52M	139.73M	106.14M	101.42M	112.51M	106.01M
Balance Sheet
Total Assets	801.72M	840.55M	621.52M	583.43M	423.76M	571.73M
Cash, Cash Equivalents and Short-Term Investments	342.23M	383.33M	368.22M	436.62M	335.81M	476.89M
Total Debt	6.61M	6.94M	151.00K	1.14M	526.00K	2.55M
Total Liabilities	165.93M	160.96M	114.81M	81.59M	47.95M	48.39M
Stockholders Equity	635.79M	679.59M	506.70M	501.84M	375.81M	523.34M
Cash Flow
Free Cash Flow	180.28M	195.90M	126.90M	119.91M	167.42M	150.73M
Operating Cash Flow	182.20M	198.07M	127.04M	120.32M	167.89M	151.97M
Investing Cash Flow	-41.44M	-177.60M	90.91M	-114.33M	136.13M	-119.26M
Financing Cash Flow	-168.39M	-28.35M	-148.72M	-17.28M	-302.59M	12.21M

Corcept Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 79.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Positive. The current price of 79.8 is above the 20-day moving average (MA) of 71.39, above the 50-day MA of 71.01, and above the 200-day MA of 66.70, indicating a bullish trend. The MACD of 1.13 indicates Negative momentum. The RSI at 68.64 is Neutral, neither overbought nor oversold. The STOCH value of 82.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CORT.

Corcept Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	76 Outperform	$7.92B	66.90	21.42%	―	25.71%	4.48%
JAZZ	64 Neutral	7.86B	-19.44	-10.92%	―	4.52%	-205.13%
AXSM	58 Neutral	5.82B	-23.39	-337.87%	―	69.83%	22.16%
RYTM	55 Neutral	6.38B	-32.65	-137.04%	―	53.55%	30.87%
RVMD	52 Neutral	8.19B	-10.04	0.00%	―	-100.00%	-23.49%
LEGN	50 Neutral	6.36B	-19.83	-31.46%	―	75.01%	-13.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Corcept Therapeutics Corporate Events

Corcept Therapeutics’ New Drug Application Accepted by FDA

On September 10, 2025, Corcept Therapeutics announced that the FDA has accepted its New Drug Application for relacorilant, intended for treating patients with platinum-resistant ovarian cancer. This acceptance, based on positive Phase 2 and 3 trial results, marks a significant step towards offering a new treatment option for this challenging condition, with the FDA assigning a PDUFA date of July 11, 2026. Relacorilant, which has shown improved progression-free and overall survival rates without increasing safety risks, could potentially redefine treatment for this form of cancer.

The most recent analyst rating on (CORT) stock is a Buy with a $79.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.